Pacific Biosciences (PACB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 59,197 | 56,060 | 78,672 | 99,868 | 76,946 |
| Marketable Securities | 284,603 | 334,561 | 393,165 | 410,276 | 485,268 |
| Receivables | 31,645 | 27,524 | 29,383 | 32,433 | 30,323 |
| Inventories | 54,007 | 58,755 | 65,737 | 68,594 | 67,343 |
| TOTAL | $444,923 | $495,681 | $584,234 | $628,139 | $677,024 |
| Non-Current Assets | |||||
| PPE Net | 24,794 | 30,505 | 31,952 | 34,910 | 37,291 |
| Intangibles | 335,943 | 707,333 | 805,487 | 812,339 | 912,392 |
| Other Non-Current Assets | 55,129 | 26,928 | 28,379 | 34,103 | 43,213 |
| TOTAL | $415,866 | $764,766 | $865,818 | $881,352 | $992,896 |
| Total Assets | $860,789 | $1,260,447 | $1,450,052 | $1,509,491 | $1,669,920 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 14,037 | 16,590 | 12,064 | 17,488 | 21,006 |
| Accrued Expenses | 29,337 | 22,595 | 19,183 | 22,456 | 21,991 |
| Other current liabilities | 5,570 | 3,224 | 783 | 6,747 | 2,836 |
| TOTAL | $66,602 | $66,299 | $59,997 | $78,390 | $72,951 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 15,241 | 13,864 | 17,292 | 19,212 | 17,346 |
| Other Non-Current Liabilities | 696,694 | 681,654 | 931,478 | 932,695 | 941,825 |
| TOTAL | $702,549 | $687,554 | $936,933 | $938,401 | $947,952 |
| Total Liabilities | $769,151 | $753,853 | $996,930 | $1,016,791 | $1,020,903 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 300,085 | 297,852 | 273,864 | 272,529 | 272,356 |
| Common Shares | 300 | 294 | 274 | 272 | 272 |
| Retained earnings | -2,575,001 | -2,148,926 | -2,151,297 | -2,090,572 | -1,917,253 |
| Other shareholders' equity | 381 | 422 | 1,553 | -523 | -306 |
| TOTAL | $91,638 | $506,594 | $453,122 | $492,700 | $649,017 |
| Total Liabilities And Equity | $860,789 | $1,260,447 | $1,450,052 | $1,509,491 | $1,669,920 |